{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.005","pValueComment":"P-value generated based on z-test where z-test statistic is the ratio of the log-transformed ratio of the cumulative hazards in the 2 treatment arms divided by the square root of the variance.","statisticalComment":"The variance was estimated using the delta method and Greenwood's formula.","statisticalMethod":"z-test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"61.7","upperLimit":"70.4","value":"66.3"},{"groupId":"OG001","lowerLimit":"48.9","upperLimit":"61.8","value":"55.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"476"},{"groupId":"OG001","value":"237"}],"units":"Participants"}],"description":"OS24 was defined as the percentage of patients who were alive at 24 months after randomization per the Kaplan-Meier estimate of OS at 24 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients in the durvalumab (MEDI4736) monotherapy group were to receive durvalumab 10 mg/kg Q2W via intravenous infusion for up to 12 months.","id":"OG000","title":"Durvalumab (MEDI4736)"},{"description":"Patients in the placebo group were to receive matching placebo for intravenous infusion Q2W for up to 12 months.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"FAS included all randomized patients, analyzed on an ITT basis.","reportingStatus":"POSTED","timeFrame":"From baseline until death due to any cause. Assessed until 22 Mar 2018 DCO; up to a maximum of approximately 4 years.","title":"Percentage of Patients Alive at 24 Months (OS24)","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}